Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China

Background: This prespecified subgroup analysis of the FIDELIO-DKD trial aimed to evaluate the efficacy and safety of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) in China. Methods: 372 participants were recruited from 67 centers in China and randomize...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Haitao Zhang, Jingyuan Xie, Chuanming Hao, Xuemei Li, Dalong Zhu, Hongguang Zheng, Xudong Xu, Zhaohui Mo, Weiping Lu, Yibing Lu, Chaoqing Wu, Nanwei Tong, Li Wang, Zhihong Liu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Karger Publishers 2023-08-01
Edice:	Kidney Diseases
Témata:	type 2 diabetes chronic kidney disease finerenone renal outcomes
On-line přístup:	https://beta.karger.com/Article/FullText/531997
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!